[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"case:lead-pharma-medicine-bv-09172969:header:guest:personal:":3,"case:lead-pharma-medicine-bv-09172969:investigations:guest:personal::{}":80},{"id":4,"slug":5,"name":6,"trade_names":7,"status":8,"procedure":9,"procedure_type":10,"insolvency_number":29,"case_number":29,"declared_on":30,"terminated_on":31,"termination_reason":32,"kvk_number":33,"legal_form":34,"sbi":14,"court":37,"judge":40,"judge_source":41,"curator":42,"location":46,"counts":56,"pages":61,"follower_count":60,"report_count":57,"last_report_on":73,"last_update_at":74,"freshness":75,"linked":79},"01M3SJFSJCWBFFNRZ7ERDWZQ0C","lead-pharma-medicine-bv-09172969","Lead Pharma Medicine B.V.",[],"terminated","bankruptcy",{"id":11,"key":9,"family":12,"name":13,"short_name":14,"legal_basis":15,"features":19},"01M3Y8CPCPT53NPXHK39BWK1QY","insolvency","Faillissement",null,{"name":16,"provision":17,"url":18},"Faillissementswet","Titel I (art. 1 e.v.)","https:\u002F\u002Fwetten.overheid.nl\u002FBWBR0001860",[20,21,22,23,24,25,26,27,28],"reports","financials","creditors","assets","investigations","curator_workspace","appointments","court_decisions","portfolio_monitoring","F.01\u002F25\u002F159","2025-06-17","2026-09-29","lack_of_assets","09172969",{"value":35,"source":36},"BV","cir",{"name":38,"slug":39,"location":14},"Rechtbank Oost-Brabant","oost-brabant","mr. S.C.E.F. Moulen Janssen",{"type":36,"report_number":14,"published_on":14},{"name":43,"slug":44,"law_firm":14,"city":14,"verified":45},"mr. D.P. Schalken","dp-schalken",false,{"street":47,"house_number":48,"addition":49,"postal_code":50,"city":51,"municipality":51,"province":52,"lat":53,"lng":54,"kind":55,"source":36},"Kloosterstraat","9","RK","5349AB","Oss","Noord-Brabant",51.760717,5.533719,"business",{"reports":57,"documents":58,"assets":59,"investigations":60,"news":60},9,13,6,0,{"overview":62,"reports":64,"financials":65,"investigations":66,"assets":67,"timeline":68,"documents":69,"news":70,"company":71,"compare":72},{"index":63,"ads":63},true,{"index":63,"ads":63},{"index":63,"ads":63},{"index":45,"ads":45},{"index":63,"ads":45},{"index":63,"ads":45},{"index":63,"ads":45},{"index":45,"ads":45},{"index":63,"ads":45},{"index":45,"ads":45},"2026-08-11","2026-10-04T17:34:33+00:00",{"last_checked_at":76,"last_reconciled_at":77,"stale":45,"status":78},"2026-10-10T15:00:12+00:00","2026-10-11T04:06:37+00:00","current",{"continued_from":14,"continued_as":14},{"data":81,"meta":205},[82,114,127,137,152,165,177,185,192],{"topic":83,"state":84,"category":85,"states":86,"source":100},"legality_review","mentioned","automated",[87,91,94,97],{"report_number":88,"report_date":89,"state":90},1,"2025-07-14","investigating",{"report_number":92,"report_date":93,"state":90},2,"2025-10-14",{"report_number":95,"report_date":96,"state":90},3,"2026-01-14",{"report_number":98,"report_date":99,"state":84},4,"2026-04-08",{"id":101,"category":85,"method":102,"source_type":103,"document":104,"page":109,"section":110,"excerpt":111,"certainty":112,"curator_verified_at":14,"processed_at":113},318138,"deterministic","cir_report",{"id":105,"title":106,"report_number":98,"report_date":99,"published_on":99,"page_count":107,"url":108,"available":63},"01M3SJG6EV72GZJ4NWXZ6V4RQB","Verslag: 08-04-2026",17,"https:\u002F\u002Ffaillissement.app\u002Fdocuments\u002F01M3SJG6EV72GZJ4NWXZ6V4RQB.pdf",11,"7.1 Boekhoudplicht","Voldaan.",0.5,"2026-10-02T18:43:03+00:00",{"topic":115,"state":84,"category":85,"states":116,"source":121},"director_liability",[117,118,119,120],{"report_number":88,"report_date":89,"state":90},{"report_number":92,"report_date":93,"state":90},{"report_number":95,"report_date":96,"state":90},{"report_number":98,"report_date":99,"state":84},{"id":122,"category":85,"method":102,"source_type":103,"document":123,"page":124,"section":125,"excerpt":126,"certainty":112,"curator_verified_at":14,"processed_at":113},318136,{"id":105,"title":106,"report_number":98,"report_date":99,"published_on":99,"page_count":107,"url":108,"available":63},12,"7.5 Onbehoorlijk bestuur","Toelichting Er is geen sprake van onbehoorlijk bestuur. De gemaakte intercompany-afspraken over de toebedeling van kosten en activa binnen het concern w erd achterhaald door het uitgesproken faillissement van Lead Pharma Holding B.V.",{"topic":128,"state":84,"category":85,"states":129,"source":134},"bookkeeping_duty",[130,131,132,133],{"report_number":88,"report_date":89,"state":90},{"report_number":92,"report_date":93,"state":90},{"report_number":95,"report_date":96,"state":90},{"report_number":98,"report_date":99,"state":84},{"id":135,"category":85,"method":102,"source_type":103,"document":136,"page":109,"section":110,"excerpt":111,"certainty":112,"curator_verified_at":14,"processed_at":113},318135,{"id":105,"title":106,"report_number":98,"report_date":99,"published_on":99,"page_count":107,"url":108,"available":63},{"topic":138,"state":139,"category":85,"states":140,"source":145},"annual_accounts_filing","completed",[141,142,143,144],{"report_number":88,"report_date":89,"state":139},{"report_number":92,"report_date":93,"state":139},{"report_number":95,"report_date":96,"state":139},{"report_number":98,"report_date":99,"state":139},{"id":146,"category":85,"method":102,"source_type":103,"document":147,"page":124,"section":148,"excerpt":149,"certainty":150,"curator_verified_at":14,"processed_at":151},134817,{"id":105,"title":106,"report_number":98,"report_date":99,"published_on":99,"page_count":107,"url":108,"available":63},"7.2 Depot jaarrekeningen","De jaarrekening 2023 is gedeponeerd op 4 juli 2024.",0.7,"2026-09-30T16:31:29+00:00",{"topic":153,"state":139,"category":85,"states":154,"source":159},"causes_investigation",[155,156,157,158],{"report_number":88,"report_date":89,"state":139},{"report_number":92,"report_date":93,"state":139},{"report_number":95,"report_date":96,"state":84},{"report_number":98,"report_date":99,"state":139},{"id":160,"category":85,"method":102,"source_type":103,"document":161,"page":162,"section":163,"excerpt":164,"certainty":150,"curator_verified_at":14,"processed_at":151},134802,{"id":105,"title":106,"report_number":98,"report_date":99,"published_on":99,"page_count":107,"url":108,"available":63},5,"1.5 Oorzaak faillissement","Tot heden is de curator het volgende gebleken uit gesprekken met het bestuur en betrokkenen, maar dit vormt geen conclusie. Lead Pharma Medicine B.V. exploiteert een farmaceutisch onderzoeks- en ontw ikkelbedrijf. Daartoe verricht zij onderzoek naar nieuw e medicijnen ter genezing van kanker en auto-immuunziekten. Medicijnonderzoek is een langdurig en kostbaar traject. Van een idee naar verkoop du",{"topic":166,"state":84,"category":85,"states":167,"source":172},"paulianas",[168,169,170,171],{"report_number":88,"report_date":89,"state":90},{"report_number":92,"report_date":93,"state":90},{"report_number":95,"report_date":96,"state":90},{"report_number":98,"report_date":99,"state":84},{"id":173,"category":85,"method":102,"source_type":103,"document":174,"page":124,"section":175,"excerpt":176,"certainty":112,"curator_verified_at":14,"processed_at":113},318137,{"id":105,"title":106,"report_number":98,"report_date":99,"published_on":99,"page_count":107,"url":108,"available":63},"7.6 Paulianeus handelen","Nee Toelichting Er is geen sprake van paulianeus handelen.",{"topic":178,"state":179,"category":14,"states":180,"source":14},"related_party_transactions","not_mentioned",[181,182,183,184],{"report_number":88,"report_date":89,"state":179},{"report_number":92,"report_date":93,"state":179},{"report_number":95,"report_date":96,"state":179},{"report_number":98,"report_date":99,"state":179},{"topic":186,"state":179,"category":14,"states":187,"source":14},"fraud_report",[188,189,190,191],{"report_number":88,"report_date":89,"state":179},{"report_number":92,"report_date":93,"state":179},{"report_number":95,"report_date":96,"state":179},{"report_number":98,"report_date":99,"state":179},{"topic":193,"state":84,"category":85,"states":194,"source":199},"proceedings",[195,196,197,198],{"report_number":88,"report_date":89,"state":84},{"report_number":92,"report_date":93,"state":84},{"report_number":95,"report_date":96,"state":84},{"report_number":98,"report_date":99,"state":84},{"id":200,"category":85,"method":102,"source_type":103,"document":201,"page":202,"section":203,"excerpt":204,"certainty":112,"curator_verified_at":14,"processed_at":151},134820,{"id":105,"title":106,"report_number":98,"report_date":99,"published_on":99,"page_count":107,"url":108,"available":63},16,"9.1 Naam wederpartijen","Er is niet gebleken van procedures.",{"reports":206},[207,209,211,213],{"id":208,"number":88,"published_on":89},"01M3SJFV54Q9T37PDS1XMEDQEQ",{"id":210,"number":92,"published_on":93},"01M3SJFWV1HQCMXQDQAEJZ5HED",{"id":212,"number":95,"published_on":96},"01M3SJFZZX1K9WBY6WZ9W86CVW",{"id":214,"number":98,"published_on":99},"01M3SJG4ZHENMD35XVB72FSVJQ"]